Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

Sanofi has discontinued clinical development of amlitelimab, an OX40-ligand monoclonal antibody, for moderate-to-severe atopic dermatitis. The company determined that efficacy and safety evidence does not support further development, as the drug would not represent a meaningful improvement over current standard of care. The decision does not impact 2026 financial guidance. Amlitelimab development continues in celiac disease with results expected in H2 2026.